Bachem expands multi-site production capacities to meet rising demand

Bachem, a Swiss peptide and oligonucleotide manufacturer, has announced expansion of its multi-site network, launching major investment at sites in Switzerland, the USA and the UK.

The major investment is across its site network, with new funding to improve production facilities at their Bubendorf, Vista and St Helens sites, along with a new site in Sisseln.

The funding comes in response to skyrocketing demand for weight loss drugs, with the global market for obesity drugs expected to increase by more than 15-fold by 2030.